Growth Analyser Growth Analyser

Nippon India Nifty Pharma ETF

Direct · Growth Equity ETFs
NAV i
+0.05% on the day · 20 Nov 2026
SIP calculator Fund card

In plain words

as of 20 Nov 2026
Returns vs similar funds

Over 5 years it returned 16.6% a year, above the middle Equity ETFs fund (11.7%) by 4.9 points.

Against its benchmark

Trailed its benchmark by 0.0 points a year over 5 years (16.6% vs 16.6%).

How bumpy the ride was

Its ups and downs have been smaller than most funds in its category. Volatility 15.0% vs a category middle of 18.3%.

Its worst fall

The deepest fall was −21.0% (Oct 2021 to Mar 2023); it recovered in 136 days.

How often a year ended in a loss

Of every 1-year period since launch, 26% ended below where they started. The middle 1-year result was 13.5%.

Key facts

Fund house
Nippon India Mutual Fund
Category
Equity ETFs (SEBI)
Plan & option
Direct · Growth
Benchmark i
NIFTY Pharma TRI (tracked via Nippon India Nifty Pharma ETF - Direct Plan)
First NAV
6 Jul 2021 · 5.4 years of history · 1,328 NAVs
AMFI code
149008
ISIN
INF204KC1089
Expense ratio i
0.23%
Fund size
₹1,756 Cr

How ₹100 grew

Loading chart…

Returns

Up to 1 year: total change. Longer: yearly (CAGR) i
1M3M6MYTD1Y3Y5Y7Y10YSince launch
This fund+10.82%+7.43%+14.54%+25.40%+25.57%+22.02%+16.60%——+14.02%
NIFTY Pharma TRI*+10.82%+7.43%+14.54%+25.40%+25.57%+22.02%+16.60%———
Equity ETFs middle fund i+9.21%+2.42%+8.27%+2.25%+1.02%+14.23%+11.71%+14.45%+13.56%—

Category middle = median Direct Growth fund in Equity ETFs (22 funds with 3 years). * Benchmark approximated by Nippon India Nifty Pharma ETF - Direct Plan, which runs slightly below the index by its costs. Blank means not enough history, never zero.

Risk and risk-adjusted return

Last 36 months · risk-free rate 6.5%
Volatility i
14.96%
Category middle 18.3%
Downside volatility i
9.04%
Sharpe ratio i
1.04
Category middle 0.41
Sortino ratio i
1.72
Calmar ratio i
1.33
Positive months
61%
Best day (3Y)
+3.64%
Worst day (3Y)
−4.03%

Against its benchmark

NIFTY Pharma TRI · 36 monthly returns
Alpha i
+0.00%
Beta i
1.00
R² i
100%
Up capture i
100%
Down capture i
100%
Tracking error i
0.00%
Information ratio i
—
Treynor ratio i
0.14

The worst it has been

Deepest fall i
−20.98%
Oct 2021 → Mar 2023
Time to recover i
136 days
27 Jul 2023
Below its high today i
−1.75%
Deepest fall, last 3Y
−16.55%

Every 1-year period i

Best
+65.21%
Middle
+13.46%
Worst
−15.30%
Ended in a loss i
26%
3-year middle
+20.51%
3-year worst
+12.81%

One 5-year number depends on its start date. These show what happened across every start date in the fund's life.

What it holds

filed for 31 Oct 2026

Asset mix

Indian equity99.97%

How concentrated

Stocks
20
Top 5
56.0%
Top 10
78.6%
Top 20
100.0%
Largest holding
18.61%
Effective stocks i
11.5
Sectors
1
Cash & money market
0.0%

Largest sector: Pharmaceuticals & Biotechnology at 100.0%.

Largest holdings

HoldingSectorWeight
Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology18.61%
Divi's Laboratories LimitedPharmaceuticals & Biotechnology12.28%
Laurus Labs LimitedPharmaceuticals & Biotechnology9.26%
Dr. Reddy's Laboratories LimitedPharmaceuticals & Biotechnology8.15%
Cipla LimitedPharmaceuticals & Biotechnology7.67%
Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology6.71%
Lupin LimitedPharmaceuticals & Biotechnology4.83%
Aurobindo Pharma LimitedPharmaceuticals & Biotechnology4.59%
Glenmark Pharmaceuticals LimitedPharmaceuticals & Biotechnology3.42%
Zydus Lifesciences LimitedPharmaceuticals & Biotechnology3.05%
Alkem Laboratories LimitedPharmaceuticals & Biotechnology3.05%
Mankind Pharma LimitedPharmaceuticals & Biotechnology2.79%
IPCA Laboratories LimitedPharmaceuticals & Biotechnology2.65%
Gland Pharma LimitedPharmaceuticals & Biotechnology2.44%
Biocon LimitedPharmaceuticals & Biotechnology2.42%
Sai Life Sciences LimitedPharmaceuticals & Biotechnology2.13%
Ajanta Pharma LimitedPharmaceuticals & Biotechnology1.58%
Wockhardt LimitedPharmaceuticals & Biotechnology1.55%
Piramal Pharma LimitedPharmaceuticals & Biotechnology1.47%
Abbott India LimitedPharmaceuticals & Biotechnology1.32%

Sectors

Pharmaceuticals & Biotechnology100.0%

What the manager did last month

30 Sep 2026 → 31 Oct 2026
Bought
₹0 Cr
Sold
₹25 Cr
New positions
0
Sold out of
0

A holding's value moves with its price; only a change in the number of shares is a decision. These lists use share counts. A split or bonus also changes share counts, so check sudden round multiples.

Trimmed 20

Sun Pharmaceutical Industries Limited₹−4.6 Cr
Divi's Laboratories Limited₹−3.1 Cr
Laurus Labs Limited₹−2.3 Cr
Dr. Reddy's Laboratories Limited₹−2.0 Cr
Cipla Limited₹−1.9 Cr
Torrent Pharmaceuticals Limited₹−1.6 Cr
Lupin Limited₹−1.2 Cr
Aurobindo Pharma Limited₹−1.1 Cr

Against similar funds

Top Equity ETFs Direct Growth funds by return. A sort by one past number, not a recommendation.

FundReturnVolatilitySharpeAlphaBetaDeepest fallStars
Nippon India ETF Nifty PSU Bank BeES
Nippon India
+25.11%26.0%0.72+0.01%1.00−73.59%Not rated
Nippon India Nifty Pharma ETF
Nippon India
+22.02%15.0%1.04+0.00%1.00−20.98%Not rated
Nippon India Nifty Auto ETF
Nippon India
+20.46%21.4%0.65−0.07%1.00−28.25%Not rated
CPSE ETF
Nippon India
+17.10%21.3%0.50——−54.09%Not rated
UTI - Nifty Next 50 Exchange Traded Fund
UTI
+17.03%20.3%0.52+0.48%1.00−40.27%Not rated
Nippon India ETF Nifty Next 50 Junior BeES
Nippon India
+16.90%20.3%0.51+0.37%1.00−40.54%Not rated
UTI - BSE Sensex Next 50 Exchange Traded Fund
UTI
+15.79%18.6%0.50——−39.95%Not rated
Nippon India ETF BSE Sensex Next 50
Nippon India
+15.60%18.5%0.49——−38.30%Not rated
UTI Nifty Bank ETF
UTI
+14.73%19.5%0.42+0.04%1.00−20.59%Not rated
Nippon India ETF Nifty Bank BeES
Nippon India
+14.65%19.5%0.42−0.03%1.00−48.57%Not rated
Compare side by side with another Equity ETFs fund

If you had run a SIP i

₹10,000 on the first NAV of every month for 5 years: ₹6,00,000 invested would be worth ₹10,11,738 on 20 Nov 2026.

XIRR, 5 years i
+20.60%
XIRR, 3 years
+19.58%
XIRR, 1 year
+34.31%

XIRR counts each instalment for the time it was invested, so it is the return a SIP investor actually got.

Try your own amount and dates

All plans and options

SchemeNAVAMFI code
Direct · Growth₹29.1863149008

About Equity ETFs funds

The rule
Exchange-traded fund that tracks an equity index; bought on the stock exchange.
Who it can suit
Investors with a demat account who want low-cost index exposure.
Typical holding period
5 years or more

Questions people ask

What is the NAV of Nippon India Nifty Pharma ETF?

₹29.1863 as of 20 Nov 2026, from AMFI's daily NAV file. NAVs are published once every business day after markets close.

Direct or Regular: what is the difference?

Same portfolio. Regular pays a distributor commission inside its fee, so it returns a little less every year.

Growth or IDCW?

Growth reinvests everything. IDCW pays some out, so its NAV drops after each payout and its NAV-based return understates what investors received.

How are these numbers calculated?

Every figure is computed by Growth from the fund's published NAV history. See How we calculate.

Search Growth